Hello, everyone, and how are you this morning? We are doing just fine, thank you, despite the gray skies hovering over the exceedingly quiet and nearly balmy Pharmalot campus. Although it appears snowflakes should be falling, given the time of year, it is actually quite mild in these parts. Nonetheless, we are savoring another hot cup of stimulation to help the neurons do their thing. Please feel free to join us. Meanwhile, here are a few items of interest. Hope your day goes well, of course, and please do stay in touch.
Moderna (MRNA) shipped the first batch of its coronavirus vaccine to U.S. government researchers, who will launch the first human tests of whether the shot could help suppress the epidemic originating in China, The Wall Street Journal reports. The National Institute of Allergy and Infectious Diseases expects to start a clinical trial of about 20 to 25 healthy volunteers by the end of April, testing whether two doses of the shot are safe and induce an immune response likely to protect against infection. Initial results could become available in July or August.